Paid Clinical Trials Cheyenne
Discover 13 paid clinical trials in Cheyenne, Wyoming. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Amlitelimab with CorticosteroidsA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
Sponsor:
Sanofi
Location:
Code:
NCT06241118
Conditions
Dermatitis Atopic
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Interventions
Amlitelimab
Placebo
Topical corticosteroids
Topical tacrolimus or pimecrolimus
Genetic StudiesMolecular Genetics Studies of Cancer Patients and Their Relatives
Sponsor:
City of Hope Medical Center
Location:
Code:
NCT04185935
Conditions
Malignant Neoplasm
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Accepted
Interventions
Biospecimen Collection
Questionnaire Administration
Bimatoprost & LUMIGANBioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
Sponsor:
Amneal Pharmaceuticals, LLC
Location:
Code:
NCT05401357
Conditions
Glaucoma, Open-Angle
Ocular Hypertension
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Test - Bimatoprost 0.01% Ophthalmic Solution
Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)
Visceral AdiposityEvaluation of Body Composition Improvement With Visceral Adiposity-Focused Anti-Obesity Telehealth Program
Sponsor:
20Lighter
Location:
Code:
NCT05219240
Conditions
Obesity
Cardiovascular Diseases
Metabolic Syndrome
Metabolic Disease
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
20Lighter Program
Access SupportNavigation and Parent Peer Support to Promote Access
Sponsor:
University of Colorado, Denver
Location:
Code:
NCT04029220
Conditions
Mental Disorder, Child
Mental Health
Family Health
Eligibility Criteria
Sex: All
Age: 1 - 70+
Healthy Volunteers: Accepted
Interventions
Parent Peer Navigation
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Observational StudyPrevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
Sponsor:
Ensoma
Location:
Code:
NCT06605378
Conditions
Chronic Granulomatous Disease (CGD)
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
Encorafenib & BinimetinibA Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
Sponsor:
SWOG Cancer Research Network
Location:
Code:
NCT04511013
Conditions
Acral Lentiginous Melanoma
Clinical Stage IV Cutaneous Melanoma AJCC v8
Metastatic Cutaneous Melanoma
Metastatic Malignant Neoplasm in the Brain
Metastatic Melanoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Binimetinib
Encorafenib
Ipilimumab
Nivolumab
Physical ActivitySustaining Physical Activity After Cancer Exercise Sessions
Sponsor:
Colorado State University
Location:
Code:
NCT06359210
Conditions
Exercise Oncology
Physical Activity Behavior
Behavior Change Interventions
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Responder Monthly Behavior Change Discussion Sessions
Incomplete Responder Monthly Behavior Change Discussion Sessions
Incomplete Responder Monthly Behavior Change Discussion Sessions + Bi-Weekly Exercise Sessions
Carboplatin with IohexolEvaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Sponsor:
NRG Oncology
Location:
Code:
NCT03997370
Conditions
Malignant Solid Neoplasm
Eligibility Criteria
Sex: Male
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Carboplatin
Iohexol
Olaparib & BevacizumabTesting Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Sponsor:
NRG Oncology
Location:
Code:
NCT06580314
Conditions
Fallopian Tube Endometrioid Adenocarcinoma
Fallopian Tube High Grade Serous Adenocarcinoma
FIGO Stage III Ovarian Cancer 2014
FIGO Stage IV Ovarian Cancer 2014
Ovarian Carcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Bevacizumab
Biospecimen Collection
Computed Tomography
Magnetic Resonance Imaging
Olaparib